CA2992734A1 - Methods of treating developmental disorders with gaboxadol - Google Patents

Methods of treating developmental disorders with gaboxadol Download PDF

Info

Publication number
CA2992734A1
CA2992734A1 CA2992734A CA2992734A CA2992734A1 CA 2992734 A1 CA2992734 A1 CA 2992734A1 CA 2992734 A CA2992734 A CA 2992734A CA 2992734 A CA2992734 A CA 2992734A CA 2992734 A1 CA2992734 A1 CA 2992734A1
Authority
CA
Canada
Prior art keywords
gaboxadol
patient
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2992734A
Other languages
English (en)
French (fr)
Inventor
Matthew During
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CA2992734A1 publication Critical patent/CA2992734A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2992734A 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol Pending CA2992734A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US62/193,717 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US62/207,595 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US62/332,567 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US62/346,763 2016-06-07
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 2016-07-14

Publications (1)

Publication Number Publication Date
CA2992734A1 true CA2992734A1 (en) 2017-01-26

Family

ID=57774846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992734A Pending CA2992734A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Country Status (17)

Country Link
US (8) US20170014393A1 (OSRAM)
EP (2) EP4541420A3 (OSRAM)
JP (3) JP2018520189A (OSRAM)
KR (2) KR20240160666A (OSRAM)
CN (2) CN116531370A (OSRAM)
AU (2) AU2016295138B2 (OSRAM)
BR (1) BR112018000933A2 (OSRAM)
CA (1) CA2992734A1 (OSRAM)
CL (1) CL2018000142A1 (OSRAM)
CO (1) CO2018000375A2 (OSRAM)
ES (1) ES3021189T3 (OSRAM)
HK (1) HK1250951A1 (OSRAM)
IL (2) IL305342A (OSRAM)
MX (2) MX391708B (OSRAM)
PE (2) PE20190338A1 (OSRAM)
TW (2) TWI819995B (OSRAM)
WO (1) WO2017015049A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3151832T (pt) * 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
CN111432814B (zh) * 2017-11-14 2024-05-14 爱思开生物制药株式会社 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
CN112739353A (zh) * 2018-06-14 2021-04-30 奥维德医疗公司 Mir-92a或mir-145在治疗安格曼综合征中的用途
EP3823619A4 (en) * 2018-08-22 2021-11-17 Ovid Therapeutics Inc. USE OF GABOXADOL FOR TREATMENT OF GIOMETAL TRACT DISORDERS AND ASTHMA
WO2020061410A1 (en) * 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN114072154B (zh) * 2018-11-21 2024-03-08 塞迪戈Abc有限责任公司 用于治疗精神障碍的加波沙朵和锂的组合物
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
JP2022514275A (ja) 2018-12-17 2022-02-10 オービッド・セラピューティクス・インコーポレイテッド 非２４時間型睡眠覚醒障害の処置のためのガボキサドールの使用
WO2020247127A1 (en) * 2019-06-07 2020-12-10 Paxmedica, Inc. Compositions and methods for treating central nervous system disorders
JP2022540917A (ja) * 2019-07-15 2022-09-20 オービッド・セラピューティクス・インコーポレイテッド 治療的処置のためのガボキサドール含有医薬製剤
MX2022007715A (es) * 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
MXPA05013016A (es) 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
WO2005023256A1 (en) 2003-09-10 2005-03-17 Merck Sharp & Dohme Limited Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
EA200601853A1 (ru) * 2004-04-02 2007-02-27 Х. Лундбекк А/С Лечение нарушенной дыхательной функции
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
RS55585B1 (sr) * 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
JP2012501301A (ja) 2008-09-01 2012-01-19 ハー・ルンドベック・アクチエゼルスカベット ガボキサドールおよびｐａｔ１阻害薬またはｏａｔ阻害薬を含む医薬組成物
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
EP3108876A1 (en) 2011-10-13 2016-12-28 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
US20150313913A1 (en) 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
PT3151832T (pt) * 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP3334427A4 (en) 2015-08-11 2019-02-06 Ovid Therapeutics, Inc. METHOD OF SUSPENSION AND PARENTERAL FORMULATION FOR USE IN INTENSIVE TREATMENT
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
FI3364993T3 (fi) 2015-10-22 2023-01-13 Menetelmiä angelmanin oireyhtymän hoitamiseksi
WO2017205606A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN110225754A (zh) 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Also Published As

Publication number Publication date
AU2021250862A1 (en) 2021-11-04
WO2017015049A1 (en) 2017-01-26
US11096929B2 (en) 2021-08-24
JP2018520189A (ja) 2018-07-26
TW202325293A (zh) 2023-07-01
US20190255027A1 (en) 2019-08-22
CL2018000142A1 (es) 2018-07-13
US20180098974A1 (en) 2018-04-12
US12465597B2 (en) 2025-11-11
ES3021189T3 (en) 2025-05-26
JP2021130687A (ja) 2021-09-09
MX391708B (es) 2025-03-21
MX2018000745A (es) 2018-08-15
TWI819995B (zh) 2023-11-01
AU2016295138B2 (en) 2021-11-04
EP3324961B1 (en) 2025-03-19
KR20240160666A (ko) 2024-11-11
US20190117632A1 (en) 2019-04-25
US20230071127A1 (en) 2023-03-09
JP2023103375A (ja) 2023-07-26
IL256912A (en) 2018-03-29
IL256912B1 (en) 2023-09-01
CN116531370A (zh) 2023-08-04
KR20180031721A (ko) 2018-03-28
IL256912B2 (en) 2024-01-01
US20170014393A1 (en) 2017-01-19
CN108024997A (zh) 2018-05-11
CO2018000375A2 (es) 2018-04-19
AU2021250862B2 (en) 2023-11-09
EP4541420A3 (en) 2025-06-25
PE20230735A1 (es) 2023-05-03
MX2022004734A (es) 2022-05-13
AU2016295138A1 (en) 2018-02-08
US20210030727A1 (en) 2021-02-04
PE20190338A1 (es) 2019-03-07
HK1250951A1 (zh) 2019-01-18
EP4541420A2 (en) 2025-04-23
US20180338960A1 (en) 2018-11-29
EP3324961A1 (en) 2018-05-30
IL305342A (en) 2023-10-01
EP3324961A4 (en) 2019-03-13
BR112018000933A2 (pt) 2018-09-04
US20190321342A1 (en) 2019-10-24
TW201707700A (zh) 2017-03-01
EP3324961C0 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
AU2021250862B2 (en) Methods of treating developmental disorders with gaboxadol
US10426746B2 (en) Methods of treating developmental disorders with biguanides
AU2021257943A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine and/or gaboxadol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713

EEER Examination request

Effective date: 20210713